Knockdown of Y‑box‑binding protein‑1 inhibits the malignant progression of HT‑29 colorectal adenocarcinoma cells by reversing epithelial‑mesenchymal transition

Yan,Xue‑Bing; Zhu,Qing‑Chao; Chen,Hong‑Qi; Peng,Jia‑Yuan; Chao,Hong‑Lei; Du,Hang‑Xiang; Wang,Zhi‑Gang; Jin,Zhi‑Ming

doi:10.3892/mmr.2014.2545

Knockdown of Y‑box‑binding protein‑1 inhibits the malignant progression of HT‑29 colorectal adenocarcinoma cells by reversing epithelial‑mesenchymal transition

Authors:
- Xue‑Bing Yan
- Qing‑Chao Zhu
- Hong‑Qi Chen
- Jia‑Yuan Peng
- Hong‑Lei Chao
- Hang‑Xiang Du
- Zhi‑Gang Wang
- Zhi‑Ming Jin
View Affiliations

Affiliations: Department of Surgery, Sixth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200233, P.R. China
Published online on: September 5, 2014 https://doi.org/10.3892/mmr.2014.2545
Pages: 2720-2728

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Y‑box binding protein‑1 (YB‑1) has been identified as an oncoprotein in various malignancies. The aim of this study was to investigate the biological role of YB‑1 and its association with epithelial‑to‑mesenchymal transition (EMT) in colorectal cancer (CRC). The expression of YB‑1 and three EMT‑related proteins (E‑cadherin, N‑cadherin and vimentin) was analyzed in 80 CRC and matched normal tissue samples, by immunohistochemistry. The results indicated that the expression of YB‑1 was higher in CRC tissue samples than that in matched normal controls and was significantly correlated with tumor differentiation, tumor invasion, lymph node metastasis and distant metastases. Furthermore, analysis showed that YB‑1 expression was negatively correlated with E‑cadherin and positively correlated with N‑cadherin and vimentin expression. In vitro assays showed that knockdown of YB‑1 inhibited the proliferation, apoptosis resistance, invasion and migration of the HT‑29 CRC cell line. Of note, following knockdown of YB‑1, E‑cadherin expression was elevated whereas N‑cadherin and vimentin expression was reduced. Taken together, these results suggest that YB‑1 promotes the malignant progression of CRC in part through the induction of EMT, and YB‑1 may therefore be a potential novel target for CRC treatment.

View Figures

View References

1	Garcia-Albeniz X and Chan AT: Aspirin for the prevention of colorectal cancer. Best Pract Res Clin Gastroenterol. 25:461–472. 2011. View Article : Google Scholar
2	Lasham A, Samuel W, Cao H, et al: YB-1, the E2F pathway, and regulation of tumor cell growth. J Natl Cancer Inst. 104:133–146. 2012. View Article : Google Scholar : PubMed/NCBI
3	Bommert KS, Effenberger M, Leich E, et al: The feed-forward loop between YB-1 and MYC is essential for multiple myeloma cell survival. Leukemia. 27:441–450. 2013. View Article : Google Scholar : PubMed/NCBI
4	Takahashi M, Shimajiri S, Izumi H, et al: Y-box binding protein-1 is a novel molecular target for tumor vessels. Cancer Sci. 101:1367–1373. 2010. View Article : Google Scholar : PubMed/NCBI
5	Lovett DH, Cheng S, Cape L, Pollock AS and Mertens PR: YB-1 alters MT1-MMP trafficking and stimulates MCF-7 breast tumor invasion and metastasis. Biochem Biophys Res Commun. 398:482–488. 2010. View Article : Google Scholar : PubMed/NCBI
6	Choi YK, Cho SG, Choi HS, Woo SM, Yun YJ, Shin YC and Ko SG: JNK1/2 activation by an extract from the roots of Morus alba L. reduces the viability of multidrug-resistant MCF-7/Dox cells by inhibiting YB-1-dependent MDR1 expression. Evid Based Complement Alternat Med. 2013:7419852013.PubMed/NCBI
7	Wu Y, Yamada S, Izumi H, et al: Strong YB-1 expression is associated with liver metastasis progression and predicts shorter disease-free survival in advanced gastric cancer. J Surg Oncol. 105:724–730. 2012. View Article : Google Scholar : PubMed/NCBI
8	Panupinthu N, Yu S, Zhang D, et al: Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer. Oncogene. Jul 15–2013.(Epub ahead of print).
9	Imada K, Shiota M, Kohashi K, et al: Mutual regulation between Raf/MEK/ERK signaling and Y-box–binding protein-1 promotes prostate cancer progression. Clin Cancer Res. 19:4638–4650. 2013.PubMed/NCBI
10	Khan MI, Adhami VM, Lall RK, et al: YB-1 expression promotes epithelial-to-mesenchymal transition in prostate cancer that is inhibited by a small molecule fisetin. Oncotarget. 5:2462–2474. 2014.PubMed/NCBI
11	Zhang H, Cheng S, Zhang M, et al: Prostaglandin E2 promotes hepatocellular carcinoma cell invasion through upregulation of YB-1 protein expression. Int J Oncol. 44:769–780. 2014.PubMed/NCBI
12	Franco-Chuaire ML, Magda Carolina SC and Chuaire-Noack L: Epithelial-mesenchymal transition (EMT): principles and clinical impact in cancer therapy. Invest Clin. 54:186–205. 2013.PubMed/NCBI
13	David JM and Rajasekaran AK: Dishonorable discharge: the oncogenic roles of cleaved E-cadherin fragments. Cancer Res. 72:2917–2923. 2012. View Article : Google Scholar : PubMed/NCBI
14	He X, Chen Z, Jia M and Zhao X: Downregulated E-cadherin expression indicates worse prognosis in Asian patients with colorectal cancer: evidence from meta-analysis. PLoS One. 8:e708582013. View Article : Google Scholar : PubMed/NCBI
15	Toiyama Y, Yasuda H, Saigusa S, Tanaka K, Inoue Y, Goel A and Kusunoki M: Increased expression of Slug and Vimentin as novel predictive biomarkers for lymph node metastasis and poor prognosis in colorectal cancer. Carcinogenesis. 34:2548–2557. 2013. View Article : Google Scholar : PubMed/NCBI
16	Todosi AM, Gavrilescu MM, Aniţei GM, Filip B and Scripcariu V: Colon cancer at molecular level - usefulness of epithelial-mesenchymal transition analysis. Rev Med Chir Soc Med Nat Iasi. 116:1106–1111. 2012.PubMed/NCBI
17	Evdokimova V, Tognon C, Ng T, et al: Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell. 15:402–415. 2009. View Article : Google Scholar
18	Shiota M, Yokomizo A, Itsumi M, et al: Twist1 and Y-box-binding protein-1 promote malignant potential in bladder cancer cells. BJU Int. 108:E142–E149. 2011. View Article : Google Scholar : PubMed/NCBI
19	Matsushita K, Toiyama Y, Tanaka K, et al: Soluble CXCL16 in preoperative serum is a novel prognostic marker and predicts recurrence of liver metastases in colorectal cancer patients. Ann Surg Oncol. 19(Suppl 3): S518–S527. 2012. View Article : Google Scholar
20	Tang FY, Pai MH and Chiang EP: Consumption of high-fat diet induces tumor progression and epithelial–mesenchymal transition of colorectal cancer in a mouse xenograft model. J Nutr Biochem. 23:1302–1313. 2012.
21	Wu HM, Cao W, Ye D, Ren GX, Wu YN and Guo W: Contactin 1 (CNTN1) expression associates with regional lymph node metastasis and is a novel predictor of prognosis in patients with oral squamous cell carcinoma. Mol Med Rep. 6:265–270. 2012.PubMed/NCBI
22	Tiwari N, Gheldof A, Tatari M and Christofori G: EMT as the ultimate survival mechanism of cancer cells. Semin Cancer Biol. 22:194–207. 2012. View Article : Google Scholar : PubMed/NCBI
23	Bhangu A, Wood G, Mirnezami A, Darzi A, Tekkis P and Goldin R: Epithelial mesenchymal transition in colorectal cancer: Seminal role in promoting disease progression and resistance to neoadjuvant therapy. Surg Oncol. 21:316–323. 2012. View Article : Google Scholar : PubMed/NCBI
24	Zhu QC, Gao RY, Wu W and Qin HL: Epithelial-mesenchymal transition and its role in the pathogenesis of colorectal cancer. Asian Pac J Cancer Prev. 14:2689–2698. 2013. View Article : Google Scholar : PubMed/NCBI
25	Lasham A, Print CG, Woolley AG, Dunn SE and Braithwaite AW: YB-1: oncoprotein, prognostic marker and therapeutic target? Biochem J. 449:11–23. 2013. View Article : Google Scholar : PubMed/NCBI
26	Tsofack SP, Garand C, Sereduk C, et al: NONO and RALY proteins are required for YB-1 oxaliplatin induced resistance in colon adenocarcinoma cell lines. Mol Cancer. 10:1452011. View Article : Google Scholar : PubMed/NCBI
27	Jürchott K, Kuban RJ, Krech T, et al: Identification of Y-box binding protein 1 as a core regulator of MEK/ERK pathway-dependent gene signatures in colorectal cancer cells. PLoS Genet. 6:e10012312010.PubMed/NCBI
28	Hsieh AC, Liu Y, Edlind MP, et al: The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature. 485:55–61. 2012. View Article : Google Scholar
29	Schittek B, Psenner K, Sauer B, et al: The increased expression of Y box-binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance. Int J Cancer. 120:2110–2118. 2007. View Article : Google Scholar
30	Sinnberg T, Sauer B, Holm P, Spangler B, Kuphal S, Bosserfhoff A and Schittek B: MAPK and PI3K/AKT mediated YB-1 activation promotes melanoma cell proliferation which is counteracted by an autoregulatory loop. Exp Dermatol. 21:265–270. 2012. View Article : Google Scholar : PubMed/NCBI
31	Di Costanzo A, Troiano A, di Martino O, et al: The p63 protein isoform ΔNp63α modulates Y-box binding protein 1 in its subcellular distribution and regulation of cell survival and motility genes. J Biol Chem. 287:30170–30180. 2012.
32	To K, Fotovati A, Reipas KM, et al: Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance. Cancer Res. 70:2840–2851. 2010. View Article : Google Scholar : PubMed/NCBI
33	Cho SH, Park YS, Kim HJ, et al: CD44 enhances the epithelial-mesenchymal transition in association with colon cancer invasion. Int J Oncol. 41:211–218. 2012.PubMed/NCBI
34	Fujiwara-Okada Y, Matsumoto Y, Fukushi J, et al: Y-box binding protein-1 regulates cell proliferation and is associated with clinical outcomes of osteosarcoma. Br J Cancer. 108:836–847. 2013. View Article : Google Scholar : PubMed/NCBI
35	Evdokimova V, Tognon C, Ng T and Sorensen PH: Reduced proliferation and enhanced migration: two sides of the same coin? Molecular mechanisms of metastatic progression by YB-1. Cell Cycle. 8:2901–2906. 2009. View Article : Google Scholar
36	Mouneimne G and Brugge JS: YB-1 translational control of epithelial-mesenchyme transition. Cancer Cell. 15:357–359. 2009. View Article : Google Scholar : PubMed/NCBI
37	Guo TT, Yu YN, Yip GW, Matsumoto K and Bay BH: Silencing the YB-1 gene inhibits cell migration in gastric cancer in vitro. Anat Rec (Hoboken). 296:891–898. 2013. View Article : Google Scholar : PubMed/NCBI